CJC-1295 (no DAC) dosage chart
This summary table compares available dose amounts and schedules by administration route.
| Route | Dose | Frequency & duration |
|---|---|---|
| Injectable | 100–200 mcg | 1–3x daily · 8–12 wk |
CJC-1295 (no DAC) dosage by administration route
CJC-1295 (no DAC) injectable dosage
Reported-use amounts for CJC-1295 (no DAC) are 100–200 mcg per administration, 1–3x daily, for 8–12 wk. A gradual subcutaneous progression starts at 100 mcg in weeks 1–2, increases to 150 mcg in weeks 3–4, then reaches 200–300 mcg in weeks 5–12. Schedules include once-daily administration and a separate two-to-three-times-weekly pattern.[12][13]
The no-DAC form is a short-acting Modified GRF 1-29 analogue. Its pulse-oriented GH signaling differs from the prolonged action of DAC-containing CJC-1295.[1][2][3][4][5][12]
Cycle length and breaks
Injectable: 8–12 wk. A standard break interval between courses is not established.[12]
CJC-1295 (no DAC) dosage calculator
Convert your chosen CJC-1295 (no DAC) amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.
CJC-1295 (no DAC) safety and side effects
Approval and product quality
CJC-1295 (no DAC) is not an FDA-approved drug.[10]
Side effects and long-term safety
Injection-site reactions, flushing, headache, dizziness, blood-pressure symptoms and faster heart rate are relevant adverse effects. Long-term endocrine safety, glucose effects, interactions and product purity remain uncertain.[6][7][5][11]
Route-specific dosing limits
GH/IGF-1 effects and anti-doping restrictions require attention. Medical review is especially important for endocrine disease, glucose dysregulation, cancer or growth-factor-sensitive histories, pregnancy, breastfeeding, pediatric use, and competitive sport. Reported-use injectable schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[10][7][13][12]
Stacks that include CJC-1295 (no DAC)
Open a stack dosage guide for its component amounts, schedules and supporting information.
For a blend calculation, each component's amount and the final volume must be known. A total blend weight alone cannot tell you the dose of each component.
Common CJC-1295 (no DAC) dosage questions
What is the CJC-1295 no DAC dose?
Common Modified GRF 1-29 protocols usually use 100-200 mcg per dose, 1-3 times daily, with morning, post-workout, or before-bed timing.
Is there a standard human dose of CJC-1295 (no DAC)?
A transferable human dose for CJC-1295 (no DAC) has not been established. A product strength or reminder amount does not establish a treatment regimen.[12]
Does CJC-1295 (no DAC) have a standard cycle or break interval?
Injectable: 8–12 wk. A standard break interval between courses is not established.[12]
